Doxecitin / Doxribtimin (1) – Kygevvi®
Thymidine kinase 2 deficiency
Characteristics
| Start date | 15.08.2026 |
|---|---|
| Resolution | 04.02.2027 – active procedure |
| INN | Doxecitin/Doxribtimin |
| Brand name | Kygevvi® |
| Pharm. company | UCB Pharma GmbH |
| G-BA Procedure ID | D-1368 |
| Therapeutic area | Other diseases Orphan |
| Reason for procedure | Initial assessment |
Associated procedures
| Doxecitin / Doxribtimin (1) | Kygevvi® | UCB Pharma GmbH | Thymidine kinase 2 deficiency | n.d. | active procedure Orphan |
<< List of all resolutions